OR WAIT 15 SECS
Xellia, a generic anti-infective drug manufacturing company, is constructing a laboratory services building at its manufacturing site in Budapest, Hungary.
Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on anti-infective treatments, broke ground for a new 10-million USD expansion of its Budapest manufacturing facility, which will include product stability and release testing capabilities. A new multi-story, 3000-m2 centralized laboratory services building is being constructed next to Xellia’s API manufacturing plant, and will be completed in the summer of 2017.
The building will house microbiology and chemical analytical laboratories as well as administrative offices. The company also intends to extend its team with up to 80 new roles in manufacturing, product testing, and quality assurance. The expansion will also strengthen product-release and stability-testing services for finished dosage forms and APIs produced across many of the company’s other international sites.
“With antimicrobial resistance posing a very real international threat, our work in the production of generic anti-infectives is especially important,” said Carl-Ã ke Carlsson, CEO of Xellia, in a press release. “The Centralized Laboratory Services building will ensure that, as our global production volumes continue to increase in response to customer demand, we have the expertise and the capacity to continue to deliver effective and quality assured anti-infective products.”
Source: Xellia Pharmaceuticals